Results 251 to 260 of about 87,811 (348)

Determinants of variation in analgesic and opioid prescribing practice in an emergency department

, 2006
Alan Heins, BS Marianthe Grammas, Janet Kaye Heins, Melissa W. Costello, Kun Huang, Satya Mishra   +5 more
openalex   +2 more sources

Trends of Dispensed Opioids Prescribed by Australian Dentists: 2013–2022

Community Dentistry and Oral Epidemiology, EarlyView.
ABSTRACT Background In Australia, the prescribing of opioid medicines by dentists has increased in recent years, despite opioids not being first‐line treatment for dental pain. The aim of this longitudinal study was to examine the dispensing of opioids prescribed by dentists in Australia during 2013–2022.
Leanne Teoh, Marietta Taylor, Erin Kelty, Frank M. Sanfilippo, Mathew Lim, Michael McCullough, Christopher Etherton‐Beer, Alex Park, David Preen, Amy Page   +9 more
wiley   +1 more source

A Scoping Review of the Emergence of Novel Synthetic Opioids in Australian Drug Markets: What Does This Mean for Harm Reduction Responses?

Drug and Alcohol Review, EarlyView.
ABSTRACT Issues Rising synthetic opioid deaths in North America, and the emergence of nitazene harms has driven concern about novel synthetic opioids (NSO) in Australia. This scoping review aimed to map what is known about NSOs in Australia. Approach Scoping review of peer‐reviewed and grey literature on NSO detections and harms.
Emmanuel Mammoliti, Suzanne Nielsen, Amanda Roxburgh   +2 more
wiley   +1 more source

Perceptions of disposal options for unused opioid analgesics among people who have been prescribed an opioid analgesic in North Carolina. [PDF]

Am J Drug Alcohol Abuse
Joyce C, Richman AR, Cox MJ, Helme DW, Jackson JT, Sesay M, Egan KL.   +6 more
europepmc   +1 more source

Emergence of Medetomidine in the Unregulated Drug Supply and Its Association With Hallucinogenic Effects

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction The unregulated drug supply in the United States is rapidly evolving, and veterinary tranquillisers have emerged as adulterants of concern, especially in illicitly‐manufactured fentanyl. Following the proliferation of xylazine, medetomidine, a more potent sedative, has recently appeared in multiple US states.
Adams L. Sibley, Madigan L. Bedard, Samuel Tobias, Brooke A. Chidgey, Irina G. Phillips, Alice Bell, Nabarun Dasgupta   +6 more
wiley   +1 more source

[The relevant role of caregivers of patients using opioid analgesics]. [PDF]

Farm Comunitarios
Hernández-García V, Alberto-Armas D, Hardisson-de-la-Torre A, Rubio-Armendáriz C.   +3 more
europepmc   +1 more source

Good Practice in Postoperative and Procedural Pain Management 2nd Edition [PDF]

, 2012
CARTER, BERNIE, Curry, Joe, Howard, Richard, Jain, Anoo, Liossi, Christina, Morton, Neil, Rivett, Kate, Rose, Mary, Tyrell, Jennifer, Walker, Suellen, Williams, Glynn   +10 more
core  

The Efficacy of the Non-Opioid Analgesics Parecoxib, Paracetamol and Metamizol for Postoperative Pain Relief After Lumbar Microdiscectomy

, 2006
U. Grundmann, Clemens Wörnle, A. Biedler, Sascha Kreuer, Marc Wrobel, W. Wilhelm   +5 more
openalex   +1 more source

Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction The global drug market has seen an emergence of potent synthetic opioids, including benzimidazole‐derived substances known as nitazenes. These compounds have been implicated in fatal and non‐fatal overdoses. This review aims to synthesise current evidence on the pharmacological effects, potency and naloxone responsiveness of new ...
Suzanne Nielsen, João Pedro Silva, Jermaine D. Jones, Alex Krotulski, Dilkushi Poovendran, Deusdedit Muzangizi, Gilles Forte, Jason White, Sandra D. Comer   +8 more
wiley   +1 more source

A closer look at Doleac and Mukherjee (2022) and the effects of naloxone access laws on opioid ER admissions

Economic Inquiry, EarlyView.
Abstract In their 2022 study, ‘The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime,’ Doleac and Mukherjee conclude that broadening access to a life‐saving drug—naloxone—does not reduce opioid‐related mortality as the drug simultaneously encourages riskier drug use. I show issues with their data, design, and estimation methods. For
Sergey Alexeev
wiley   +1 more source